J Schultheiss1, C Seebach2, D Henrich1, K Wilhelm1, J H Barker1, J Frank1. 1. Department of Trauma, Hand and Reconstructive Surgery, Johann-Wolfgang-Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany. 2. Department of Trauma, Hand and Reconstructive Surgery, Johann-Wolfgang-Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany. ccseebach@aol.com.
Abstract
INTRODUCTION: Several different synthetic and allograft bone graft substitutes are used clinically to treat large bone defects. In contrast to the "gold standard" of autologous bone grafts, these do not contain bone-forming (MSC) or vessel-forming (EPC) cells. In order to achieve the same level of success enjoyed by autologous bone grafts, they must be compatible with mesenchymal stem cells (MSC) and endothelial progenitor cells (EPC). In a previous study, we seeded MSC onto six different bone graft substitutes and then measured the cell adhesion, viability, differentiation, and morphology. In the present study, we seeded both MSC and EPC onto the same six bone graft substitutes and measured the same parameters. METHODS: In vitro, 125,000 MSC and 125,000 EPC were seeded onto Chronos(®), Vitoss(®), Actifuse(®), Biobase(®), Cerabone(®), and Tutoplast(®). Cell adhesion (fluorescence microscopy) and viability (MTT assay) were measured on days 2, 6, and 10. Osteogenic (cbfa-1, alkaline phosphatase [ALP], osteocalcin, collagen-1 alpha [Col1A]) and endothelial (von Willebrand factor [vWF], vascular endothelial growth factor [VEGF], kinase domain receptor [KDR]) gene expression were analyzed by reverse transcriptase polymerase chain reaction (RT-PCR). Morphology was described by scanning electron microscopy (SEM) at day 2. RESULTS: MSC adhered significantly better to Tutoplast(®), Chronos(®), Actifuse(®), and Biobase(®). EPC adhered better to Actifuse(®), Chronos(®), Biobase(®), and Tutoplast(®). Viability increased over time when seeded on Tutoplast(®) and Chronos(®). Osteogenic and endothelial gene expression were detectable at day 10 in cells seeded on Chronos(®), Actifuse(®), and Tutoplast(®). The best morphology of MSC and EPC was found on Tutoplast(®), Chronos(®), Actifuse(®), and Biobase(®). CONCLUSION: When bone graft substitutes are used to help fill large defects, it is important that their interaction with these cells be supportive of bone healing.
INTRODUCTION: Several different synthetic and allograft bone graft substitutes are used clinically to treat large bone defects. In contrast to the "gold standard" of autologous bone grafts, these do not contain bone-forming (MSC) or vessel-forming (EPC) cells. In order to achieve the same level of success enjoyed by autologous bone grafts, they must be compatible with mesenchymal stem cells (MSC) and endothelial progenitor cells (EPC). In a previous study, we seeded MSC onto six different bone graft substitutes and then measured the cell adhesion, viability, differentiation, and morphology. In the present study, we seeded both MSC and EPC onto the same six bone graft substitutes and measured the same parameters. METHODS: In vitro, 125,000 MSC and 125,000 EPC were seeded onto Chronos(®), Vitoss(®), Actifuse(®), Biobase(®), Cerabone(®), and Tutoplast(®). Cell adhesion (fluorescence microscopy) and viability (MTT assay) were measured on days 2, 6, and 10. Osteogenic (cbfa-1, alkaline phosphatase [ALP], osteocalcin, collagen-1 alpha [Col1A]) and endothelial (von Willebrand factor [vWF], vascular endothelial growth factor [VEGF], kinase domain receptor [KDR]) gene expression were analyzed by reverse transcriptase polymerase chain reaction (RT-PCR). Morphology was described by scanning electron microscopy (SEM) at day 2. RESULTS: MSC adhered significantly better to Tutoplast(®), Chronos(®), Actifuse(®), and Biobase(®). EPC adhered better to Actifuse(®), Chronos(®), Biobase(®), and Tutoplast(®). Viability increased over time when seeded on Tutoplast(®) and Chronos(®). Osteogenic and endothelial gene expression were detectable at day 10 in cells seeded on Chronos(®), Actifuse(®), and Tutoplast(®). The best morphology of MSC and EPC was found on Tutoplast(®), Chronos(®), Actifuse(®), and Biobase(®). CONCLUSION: When bone graft substitutes are used to help fill large defects, it is important that their interaction with these cells be supportive of bone healing.
Entities:
Keywords:
Biomaterials; Bone graft substitutes; Bone tissue engineering; Cell adhesion; Ceramics; Endothelial progenitor cell; Mesenchymal stem cell; Osteoconduction; Scaffolds
Authors: H Petite; V Viateau; W Bensaïd; A Meunier; C de Pollak; M Bourguignon; K Oudina; L Sedel; G Guillemin Journal: Nat Biotechnol Date: 2000-09 Impact factor: 54.908
Authors: Andreas Arkudas; Justus P Beier; Kristina Heidner; Jimmy Tjiawi; Elias Polykandriotis; Safwan Srour; Michael Sturzl; Raymund E Horch; Ulrich Kneser Journal: Tissue Eng Date: 2007-07
Authors: Shi Ju Zhang; Hao Zhang; Ying Jie Wei; Wen Jun Su; Zhong Kai Liao; Mai Hou; Jian Ye Zhou; Sheng Shou Hu Journal: Cell Res Date: 2006-06 Impact factor: 25.617
Authors: A Barriga; P Díaz-de-Rada; J L Barroso; M Alfonso; M Lamata; S Hernáez; J L Beguiristáin; M San-Julián; C Villas Journal: Eur Spine J Date: 2003-11-28 Impact factor: 3.134
Authors: Dirk Henrich; René Verboket; Alexander Schaible; Kerstin Kontradowitz; Elsie Oppermann; Jan C Brune; Christoph Nau; Simon Meier; Halvard Bonig; Ingo Marzi; Caroline Seebach Journal: Biomed Res Int Date: 2015-02-23 Impact factor: 3.411
Authors: Christoph Nau; Dirk Henrich; Caroline Seebach; Katrin Schröder; John H Barker; Ingo Marzi; Johannes Frank Journal: Int J Mol Med Date: 2017-02-21 Impact factor: 4.101
Authors: R Verboket; M Leiblein; C Seebach; C Nau; M Janko; M Bellen; H Bönig; D Henrich; I Marzi Journal: Eur J Trauma Emerg Surg Date: 2018-01-19 Impact factor: 3.693
Authors: Karam Eldesoqi; Caroline Seebach; Christina Nguyen Ngoc; Simon Meier; Christoph Nau; Alexander Schaible; Ingo Marzi; Dirk Henrich Journal: PLoS One Date: 2013-11-14 Impact factor: 3.240
Authors: Karam Eldesoqi; Dirk Henrich; Abeer M El-Kady; Mahmoud S Arbid; Bothaina M Abd El-Hady; Ingo Marzi; Caroline Seebach Journal: PLoS One Date: 2014-02-03 Impact factor: 3.240